Display options
Cite
Kaymaz BT, Selvi N, Gokbulut AA, et al. Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis. Am J Blood Res. 2013;3(1):58-70
Kaymaz, B. T., Selvi, N., Gokbulut, A. A., Aktan, C., Gündüz, C., Saydam, G., Sahin, F., Cetintaş, V. B., Baran, Y., & Kosova, B. (2013). Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis. American journal of blood research, 3(1), 58-70.
Kaymaz, Burçin Tezcanlı, et al. "Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis." American journal of blood research vol. 3,1 (2013): 58-70.
Kaymaz BT, Selvi N, Gokbulut AA, Aktan C, Gündüz C, Saydam G, Sahin F, Cetintaş VB, Baran Y, Kosova B. Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis. Am J Blood Res. 2013;3(1):58-70. Epub 2013 Jan 17. PMID: 23358828; PMCID: PMC3555192.
Copy Download .nbib Format: NLM
Share it on

Am J Blood Res. 2013;3(1):58-70. Epub 2013 Jan 17.

Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis.

American journal of blood research

Burçin Tezcanlı Kaymaz, Nur Selvi, Aysun Adan Gokbulut, Cağdaş Aktan, Cumhur Gündüz, Güray Saydam, Fahri Sahin, Vildan Bozok Cetintaş, Yusuf Baran, Buket Kosova

Affiliations

  1. Ege University, Faculty of Medicine, Department of Medical Biology Bornova, ?zmir, Turkey.

PMID: 23358828 PMCID: PMC3555192

Abstract

Signal transducers and activators of transcription (STAT) proteins function in the JAK/STAT signaling pathway and are activated by phosphorylation. As a result of this signaling event, they affect many cellular processes including cell growth, proliferation, differentiation, and survival. Increases in the expressions of STAT5A and STAT5B play a remarkable role in the development of leukemia in which leukemic cells gain uncontrolled proliferation and angiogenesis ability. At the same time, these cells acquire ability to escape from apoptosis and host immune system. In this study, we aimed to suppress STAT-5A and -5B genes in K562 CML cells by siRNA transfection and antisense oligonucleotides (ODN) targeting and then to evaluate apoptosis rate. Finally, we compared the transfection efficiencies of these approaches. Quantitative RT-PCR and Western blot results indicated that STAT expressions were downregulated at both mRNA and protein levels following siRNA transfection. However, electroporation mediated ODN transfection could only provide limited suppression rates at mRNA and protein levels. Moreover, it was displayed that apoptosis were significantly induced in siRNA treated leukemic cells as compared to ODN treated cells. As a conclusion, siRNA applications were found to be more effective in terms of gene silencing when compared to ODN treatment based on the higher apoptosis and mRNA suppression rates. siRNA application could be a new and alternative curative method as a supporting therapy in CML patients.

Keywords: Chronic myeloid leukemia; K562; STAT5; antisense oligonucleotides; apoptosis; siRNA knockdown

References

  1. Ann Intern Med. 2006 Dec 19;145(12):913-23 - PubMed
  2. Hematology Am Soc Hematol Educ Program. 2000;:90-109 - PubMed
  3. Biochem Pharmacol. 2006 Mar 14;71(6):713-21 - PubMed
  4. Oncogene. 2000 May 15;19(21):2505-10 - PubMed
  5. Gene. 2002 Feb 20;285(1-2):1-24 - PubMed
  6. J Cell Sci. 2004 Mar 15;117(Pt 8):1281-3 - PubMed
  7. Ann Hematol. 2013 Jan;92(2):151-62 - PubMed
  8. J Exp Med. 1999 Apr 19;189(8):1229-42 - PubMed
  9. Nat Rev Cancer. 2004 Feb;4(2):97-105 - PubMed
  10. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9742-7 - PubMed
  11. Biochemistry. 2002 Apr 9;41(14):4503-10 - PubMed
  12. Mol Cell Biol. 1998 Jul;18(7):3871-9 - PubMed
  13. Mol Ther. 2009 Jan;17(1):95-103 - PubMed
  14. Oligonucleotides. 2009 Jun;19(2):89-102 - PubMed
  15. Biochem Biophys Res Commun. 2002 Aug 30;296(4):1000-4 - PubMed
  16. Cell. 1998 May 1;93(3):385-95 - PubMed
  17. Turk J Haematol. 2005 Dec 5;22(4):161-72 - PubMed
  18. Nat Rev Drug Discov. 2009 Feb;8(2):129-38 - PubMed
  19. Cell Prolif. 2003 Oct;36(5):265-78 - PubMed
  20. Nature. 2001 May 24;411(6836):494-8 - PubMed
  21. Blood. 2001 May 1;97(9):2846-53 - PubMed
  22. J Clin Oncol. 2009 Sep 10;27(26):4422-32 - PubMed
  23. Cell Mol Biol Lett. 2003;8(2):317-31 - PubMed
  24. Leukemia. 2004 Feb;18(2):189-218 - PubMed
  25. J Biol Chem. 1996 Dec 6;271(49):31704-10 - PubMed
  26. Int J Hematol. 2000 Jun;71(4):309-19 - PubMed

Publication Types